Chugai obtained approval for additional indication and formulation for Tecentriq in PD-L1-positive triple negative breast cancer
2019-09-20
Dear Investor,
Please find attached a press release by Chugai.
Do not hesitate to contact us for any further questions.
Investors
Investor updates
stay updated
get the latest news and updates to your inbox.